Does Red Light Therapy Help with Myositis? A Comprehensive Evidence Review

Bottom line: Red light therapy (photobiomodulation) shows biological promise for reducing inflammation and supporting tissue repair, but direct clinical evidence for myositis—particularly dermatomyositis and polymyositis—remains limited. No major rheumatology or neurology guidelines currently recommend red light therapy as a primary treatment for any form of myositis. It may serve as a complementary modality, but it should not replace disease-modifying therapy.

What Is Myositis?

Myositis refers to a group of inflammatory myopathies characterized by muscle weakness, inflammation, and sometimes skin involvement. The three primary subtypes are:

Subtype	Key Features	Typical Treatment
Dermatomyositis (DM)	Proximal muscle weakness + characteristic skin rash (heliotrope, Gottron papules); often associated with malignancy in adults	Corticosteroids, methotrexate, IVIG, rituximab
Polymyositis (PM)	Proximal muscle weakness without skin involvement; T-cell mediated	Corticosteroids, azathioprine, methotrexate
Inclusion Body Myositis (IBM)	Distal and proximal weakness; asymmetric; poor response to immunosuppression	No FDA-approved therapy; IVIG may help dysphagia

The hallmark pathology involves immune-mediated muscle damage, with elevated inflammatory cytokines and, in IBM, degenerative features including protein aggregation .

What Is Red Light Therapy (Photobiomodulation)?

Red light therapy, clinically termed photobiomodulation (PBM) or low-level laser therapy (LLLT), uses non-ionizing red (630–660 nm) and near-infrared (810–850 nm) wavelengths to influence cellular activity without generating significant heat .

Mechanism of Action

Cellular Effect	How It Works
Mitochondrial activation	Photons absorbed by cytochrome c oxidase displace nitric oxide, restoring ATP production
Anti-inflammatory signaling	Downregulates NF-κB pathway; reduces TNF-α, IL-1β, IL-6
Macrophage polarization	Shifts macrophages from pro-inflammatory (M1) to tissue-repairing (M2) state
Oxidative stress reduction	Enhances endogenous antioxidant defenses

These mechanisms theoretically support its use in inflammatory muscle conditions, but biological plausibility does not equal clinical efficacy.

Current Evidence: What Do Studies Actually Show?

Preclinical Evidence

Study	Model	Findings
Carvalho et al. (2015)	Acute myositis in rats	Low-level laser therapy significantly reduced inflammatory cells, increased fibroblast proliferation, and reduced edema compared to controls (p<0.05)

This animal study suggests PBM can modulate acute muscle inflammation, but results from induced myositis in rats do not directly translate to human autoimmune myositis.

Clinical Evidence in Myositis

There are no published randomized controlled trials evaluating red light therapy specifically for dermatomyositis, polymyositis, or inclusion body myositis.

Evidence Type	Status for Myositis
RCTs	None published
Case reports	None identified for DM/PM/IBM
Case series	None identified
Expert consensus	No professional society guidelines recommend PBM for myositis

A 2019 review on laser light therapy for inflammatory and autoimmune diseases concluded that while LLLT is “promising” for skin and joint conditions, evidence is limited by “variability in methods of laser application” and “lack of evidence for laser type, dose-ranging studies, and wavelength selection” .

Related Evidence: Dermatomyositis Skin Manifestations

One case report describes successful treatment of refractory facial rash associated with dermatomyositis using narrowband intense pulsed light (IPL)—a related but distinct modality from red light therapy . This addresses cutaneous symptoms only, not muscle weakness or systemic inflammation.

Wavelength and Tissue Penetration: A Critical Limitation

A fundamental challenge for treating myositis with red light therapy is penetration depth:

Wavelength	Penetration Depth	Target Tissue
660 nm (visible red)	~2–3 mm	Skin, superficial dermis
810–850 nm (near-infrared)	~5–10 mm or more	Joint capsules, superficial muscle
Deep muscle tissue	Beyond typical PBM reach	Requires invasive delivery

Clinical implication: The quadriceps and gluteal muscles commonly affected in myositis lie deeper than what non-invasive red light devices can reliably reach. As one Mayo Clinic Connect discussion noted, rheumatologists and dermatologists have advised patients that “red light can’t penetrate deep enough through muscle tissue” .

This limitation does not rule out potential benefits from systemic or indirect effects, but it substantially constrains what surface-applied PBM can achieve for deep muscle inflammation.

Comparison: Red Light Therapy vs. Established Myositis Treatments

Treatment	Evidence Level	Route	Primary Target	Key Limitations
Corticosteroids	Established (RCT)	Oral/IV	Systemic inflammation	Long-term toxicity, osteoporosis, infection risk
Methotrexate	Established (RCT)	Oral/SC	Immune modulation	Hepatotoxicity, photosensitivity (UV)
IVIG	Established (case series/RCT for IBM dysphagia)	IV	Immune modulation	Cost, infusion burden, variable response
Rituximab	Moderate evidence	IV	B-cell depletion	Infection risk, cost
Red Light Therapy	Preclinical only for myositis	Topical	Local inflammation, mitochondrial function	No human myositis trials; penetration depth limits

Important: Red light therapy should never replace established, evidence-based treatment for myositis without specialist guidance.

Safety Considerations for Myositis Patients

Consideration	Detail
Photosensitivity	UV light is a known trigger for dermatomyositis skin flares. Red/NIR light (630–850 nm) is non-UV and does not trigger the same pathways, but clinical data in DM patients is lacking
Medication interactions	Methotrexate is associated with UV photosensitivity; interaction with red/NIR light specifically is not well-characterized. Disclose all medications to your specialist
Biphasic dose response	Too little light has no effect; too much can reduce or reverse benefit. Conservative dosing is essential
Eye protection	Near-infrared wavelengths are invisible and do not trigger blinking; use rated eye protection
Active flares	Most protocols initiate during stable/remission phases; consult specialist during severe flares

What Would a Doctor Say?

Based on current evidence, a rheumatologist or neurologist would likely say:

“There is no strong evidence that red light therapy treats myositis itself.” The absence of human clinical trials means efficacy for muscle inflammation, weakness, or systemic disease activity is unproven.
“It might help with localized symptoms.” If you have superficial muscle pain or skin involvement, PBM could theoretically provide symptomatic relief, but this is extrapolated from other conditions, not proven in myositis.
“Don’t stop your prescribed treatment.” Red light therapy is not a substitute for immunosuppression, IVIG, or other disease-modifying therapies.
“If you want to try it, do so as an adjunct—not a replacement.” Discuss with your specialist first, especially if you have photosensitivity or are on medications with unknown photochemical interactions.

Practical Guidance If Considering Red Light Therapy

If you and your specialist decide to trial PBM as a complementary approach:

Parameter	Conservative Recommendation
Wavelength	660 nm (surface) and/or 810–850 nm (deeper tissue)
Session duration	Start 3–5 minutes per site for first 2 weeks
Frequency	Every other day initially
Device quality	Look for published irradiance figures (mW/cm² at stated distance), verified wavelength peaks, FDA registration/CE marking
Tracking	Log session length, site, and any changes in pain, stiffness, or function over 4–12 weeks
Review	Reassess with your specialist after 4–6 weeks

Key Takeaways

Red light therapy has plausible anti-inflammatory mechanisms relevant to myositis, supported by preclinical research .
However, no human clinical trials have evaluated PBM for dermatomyositis, polymyositis, or IBM. Evidence for these specific conditions is absent.
Penetration depth is a major limitation for targeting deep muscle inflammation non-invasively.
PBM may have a role as a complementary modality for superficial symptoms or skin manifestations, but not as a replacement for established treatment.
Always discuss with your rheumatologist or neurologist before starting red light therapy, especially given potential photosensitivity and medication interactions.

References

Carvalho AFM, et al. The low-level laser on acute myositis in rats. Acta Cir Bras. 2015;30(12):806-11.
Zheng Y, et al. Narrowband Intense Pulsed Light Treatment for Refractory Facial Rash Associated with Dermatomyositis. Clin Cosmet Investig Dermatol. 2023;16:2481-2484.
Mayo Clinic Connect. Red Light for Myositis discussion.
Wickenheisser VA, et al. Laser Light Therapy in Inflammatory, Musculoskeletal, and Autoimmune Disease. Curr Allergy Asthma Rep. 2019;19(8):37.
Reddot LED. Red Light Therapy and Autoimmune Conditions: What the Science Actually Shows.
News-Medical. Red Light Therapy: How Light Improves Cellular Energy and Repair.
Dézsi L, et al. Inclusion body myositis—a rarely recognized disorder. Ideggyogy Sz. 2013;66(3-4):89-101.